Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.

PRNewsWire • 15 hours ago

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 17, 2026

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Forbes • Jun 17, 2026

Why Illumina (ILMN) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jun 11, 2026

Illumina (ILMN): Bullish Structure Builds After Breakout

Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.

FXEmpire • Jun 9, 2026

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights.

PRNewsWire • Jun 8, 2026

ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?

Illumina shares surge 98.7% in a year as NovaSeq X adoption accelerates, clinical sequencing demand grows, and the company tops Q1 2026 guidance.

Zacks Investment Research • Jun 3, 2026

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

Zacks Investment Research • Jun 2, 2026

Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights

BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.

Business Wire • Jun 1, 2026

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research.

PRNewsWire • May 28, 2026